ofa 1:20 dilution of rabbit complement (C; Lo-Tox, Cedarlane Laboratories Limited, Hornby, Ontario, Canada). These nylon-passed aIa + C-treated T cells were cultured in RPMI 1640 containing L-glutamine (300 ug/ml), penicillin (100 U/ml), streptomycin (100 #g/ml), 2-mercaptoethanol (5 X 10-SM), Hepes buffer (10 mM), and 2.5% human AB serum (obtained from a single donor). Cells (2.5 × 105 cells/0.2 ml) were cultured in flat-bottomed microtiter plates together with 1 × 105 to 2 × 105 spleen cells or varying numbers of tumor cells, with or without antigen. In some instances, APC were pulsed with antigen before addition to cultures. These antigen-pulsed presenting cells were prepared by incubating tumor or spleen cells in PPD 100 #g/ml for 1 h at 37 ° and washing five times in media.
Spleen cells used as APC received 2,000 rad, and tumor cells received 10,000 tad, using a 137 Cs irradiator. In all experiments the A20.3 tumor cells were also cultured alone. In addition, in some experiments IL-1 and antigen were added to cultures containing tumor cells alone; the cpm obtained did not vary whether IL-1 or antigen was present or absent. Examination of stimulated cultures containing T cells and A20.3 at day 4 revealed that cells with the morphology of tumor cells were in a state of degeneration, whereas the blasts present had the typical appearance of T lymphocytes. Stimulation was assessed at day 4 by measuring the incorporation of [3H]thymidine (1 /tCi/well) (New England Nuclear, Boston, Mass.) into macromolecules. Data are expressed as the arithmetic mean cpm. SE of the mean of the replicates was usually <10% of the mean counts and has been omitted from the tables for simplicity.
Allogeneic Mixed Lymphocyte Response (MLR). Spleen or lymph node cells from unprimed
mice were passed over nylon wool columns and treated with aIa + C. These cells (3 × 105) were cocultured with irradiated spleen cells or tumor cells, as stimulator cells, in round-bottomed microtiter wells in 0.2 ml of media, as described above. The response was assayed on day 4 by uptake of [3H]thymidine.
Antigen-reactive and Alloreactive T Cell Lines. The two antigen-reactive T cell lines (a BALB/c
OVA-specific line and a B10.A pigeon cytochrome c-specific line) were the kind gifts of Dr. Maureen Howard and Dr. Louis Matis, respectively (Laboratory of Immunology, NIAID) and were prepared by the technique of Kimoto and Fathman (20) . The T cells were maintained as long-term continuous cultures by alternating 4-d periods of restimulation with antigen and syngeneic irradiated (3,300 rad) spleen cells with 10-to 14-d periods without antigen. Antigenreactive T cells recovered at the end of a 14-d rest period were used to assay specific antigen presentation by spleen or tumor antigen-presenting cells. Two alloreactive lines, D3 and M15, were prepared from original soft agar colonies by the technique of Sredni et al. (21) and were the kind gift of Dr. Ronald Schwartz and Mrs. Chuan Chen (Laboratory of Immunology, NIAID). They are of B10.A origin and are specific for DNP-OVA presented by B10.A APC. In addition, line D3 has allospecificity for the H-2 d haplotype, and line M 15 has allospecificity for the H-2 f haplotype. The lines were assayed in the following way. T cells (1 × 104 to 2 × 104) were cocultured with 1 × 105 to 5 × 105 irradiated spleen cells or varying numbers of irradiated tumor cells in the presence or absence of antigen in flat-bottomed microtiter wells in the complete media described above, with the exception that 10% fetal calf serum was substituted for human serum.
[3H]thymidine uptake was assayed on days 3-4. Lines D3 and M15 required the presence of an IL-2-containing EL4 culture supernatant during the culture period.
IL-I Preparations.
A P388D~ culture supernatant containing IL-1 was the kind gift of Dr.
Maureen Howard and Mrs. Barbara Johnson (Laboratory of Immunology, NIAID) and was produced according to the method of Mizel and Mizel (22) . Briefly, the P388D1 macrophagelike cell line was incubated with 1 /xg/ml of phorbol myristate acetate (PMA) in media containing 1% fetal calf serum. At 5 d the supernatant was harvested and incubated twice with inactivated charcoal to remove PMA. Labeling such supernatants with radiolabeled PMA (New England Nuclear) indicated that charcoal absorption results in removal of>90% of PMA (A. L. DeFranco, unpublished observations). The absorbed supernatant was then concentrated sevenfold by vacuum dialysis. This preparation contained IL-1 activity, as assayed by induction of proliferation of C3H/HeJ thymocytes in the presence of concanavalin A. A maximum induction of proliferation was seen at a dilution of supernatant of 1:16. In most experiments, unless otherwise indicated, this preparation was used at a final concentration of 1.25% in the culture system. A highly purified preparation of murine IL-1 was the kind gift of Dr. Steven Mizel, Pennsylvania State University, State College, Pa., and has been recently described (23 (13) . Because both SAC and B cells have surface Ia molecules, one possibility was that the failure of the B cell population to stimulate was due to the lack of some secretory product possessed by authentic stimulator cells and necessary for eliciting alloreactive T cell proliferation. A very likely candidate seemed to be II-1 (24) . Indeed, Table I demonstrates that in the presence of a small amount of an I1-1-rich P388DI supernatant, an excellent allogeneic MLR was obtained using 104 to 105 cells from A20.3, an Ia antigen-positive BALB/c B cell tumor line, as stimulator cells. No significant allogeneic MLR was seen in the absence of added supernatant. Moreover, the A20.3 tumor cells did not elicit syngeneic proliferation, ruling out a nonspecific stimulatory effect of tumor or viral antigens or other immunostimulatory secretory products. The responder cell population in experiment 1 was unfractionated spleen cells. To rule out the possibility that Ia alloantigens were shed from A20 tumor cells and then taken up, reprocessed, and re-presented to the T cells by syngeneic macrophages in the responder cell population, two approaches were taken. First, as shown in Table I , experiment 2, the responder cell population was passed over nylon wool columns and then treated with an a-Ia antiserum and C to further deplete Ia antigen-bearing macrophages. The allogeneic MLR obtained using this population as responder cells was as good as that obtained using unfractionated spleen cells as the responder population. Second, blocking studies using monoelonal antibodies directed at Ia antigens present on either the responder or stimulator cell population were performed and demonstrated that antibodies directed at Ia antigens present on A20.3 stimulator cells inhibited the aUogeneie MLR. Table II * In the first two experiments, the responder ceils were nylon-column passed, oda + C-treated C3H spleen ceils, and in the third experiment, the responder cells were of C57BL/6 origin. The monoclonal reagents, MKD6, directed against a determinant in the I-A a subregion, and 10.2.16, directed against a determinant in the I-A subregion of the k haplotype, were included at a dilution of l:15 (vol/vol) in the culture system. The monoclonal reagent 14-4-4S, directed against a determinant in the I-E subregion (specificity la7), was in ascite~ form and was included at a dilution of 1:200 in the culture system. The monoclonal reagent ThB was affinity-purified hybrldoma supernatant and was used at I #g/ml final concentration. All three experiments were performed in the presence of 1 therefore assayed for their ability to stimulate an allogeneic MLR. The phenotypes of these tumors is shown in Table III . Surprisingly, as shown in Table III , only three (A20.3, M12.4, and X16C8,4) of the six tumors were able to stimulate allogeneic T cell proliferation; the three remaining tumors (K46R.18, L10A6.2, and BALENLM 17.7.2) were ineffective stimulators despite the possession of large amounts of surface Ia. There was no obvious correlation between the amount of surface Ia expressed on a tumor line as determined by fluorescence activated cell sorter analysis and its stimulatory ability (data not shown). Thus, the M12 and X16C tumor cells have relatively little surface Ia but were powerful stimulants, whereas the K46, L10A, and BALENLM 17 have large amounts of surface Ia and were poor stimulators.
A20,3 Stimulates Proliferation by an H-2 a but Not by an H-2 t Alloantigen-specific Line.
Further proof that A20.3 tumor ceils are themselves providing the alloantigenic stimulus for T cell proliferation and not simply providing a nonspecific stimulus or causing the differentiation or activation of APC in residual spleen cells was obtained by using two long-term alloreactive B10.A T cell lines. One of these lines, D3, was specific for an alloantigen of the H-2 d haplotype and the other, M15, was directed at an alloantigen of the H-2 f haplotype. The results in Table IV show that as few as 5 × 103 A20.3 cells induced proliferation by the D3 line of a magnitude greater than that elicited by 105 control BALB/c spleen cells. By contrast, the A20.3 cells were ineffective in stimulating the M15 line; this line could, however, be stimulated by B 10.M (H-2 f) spleen cells. Unlike the results obtained using whole populations of T cells, proliferation of the cloned T cells could be elicited in the absence of exogenous IL-1. The reason for this discrepancy is unclear; however, these assays were performed in the presence of a preparation of IL-2.
A20.3 Presents Antigen to In Vivo Primed T Cells.
An Ia antigen-bearing APC appears to be the cell responsible for stimulating both an allogeneic MLR and for presenting § The presence of Ia antigens on these tumor cell lines has been established by immunofluorescence and cytotoxicity with aIa alloantisera (see rcf, 18) and more recently has been confirmed with monoclonal anti-Ia reagents on a fluorescence-activated ceII sorter (Kim et aI., manuscript in preparation). antigen to antigen-reactive T cells. Table V demonstrates that a small number (10 a to 104) of A20.3 cells are capable of presenting three different antigens--OVA, PPD, and G~to T cells from primed donors. Indeed, 10 a A20.3 cells stimulated a response that was slightly greater than that stimulated by 105 B10.D2 spleen cells. As in the experiments with alloreactive T cells, the antigen-reactive T cell population has been rigorously depleted of Ia-positive cells by nylon column passage followed by treatment with an anti-Ia antiserum + C. The antigen-specific response of this T cell population to antigen in the absence of added antigen-presenting cells was minimal as shown, whereas nylon column passage alone without such treatment results in a very substantial antigen-specific response (not shown).
The experiments presented in Table V were performed in the presence of 1.25% of the IL-l-rich P388D1 PMA-stimulated supernatant. However, unlike the results obtained in the allogeneic MLR (Tables I, II , and III), it was not necessary to add exogenous IL-1 to the culture system to obtain a good antigen-specific response. As shown in Table VI , 5 x 10 a A20.3 cells stimulated a good T cell response to antigen in the absence of added IL-1. This response was, however, clearly magnified by the addition of small amounts of either crude IL-1 or of highly purified IL-1. The mechanism of the enhancement of the proliferation by exogenous IL-1 is unclear; incubation of A20.3 cells with this preparation does not increase the density of surface Ia (K. J. Kim, manuscript in preparation).
Antigen Pulsing of A20.3 Cells. Previous studies have demonstrated that antigenspecific T cell proliferation can be obtained if the antigen is present continuously 
TABLE VI

Effect of Exogeneous IL-I on Antigen Presentation by A20.3 to T Cells from
Primed Donors* during the culture period or if the APC are first pulsed with the antigen, washed to remove unbound antigen, and then cocultured with the antigen-reactive T cells (25) .
To determine whether A20.3 cells could be effectively pulsed with antigen or if they required the continuous presence of antigen to stimulate an antigen-specific T cell response, we incubated A20.3 cells and control spleen cells with PPD (100/~g/ml) for 1 h. The cells were then washed extensively (five times) to remove unbound antigen and added to PPD-reactive T cells. Table VII shows that l05 pulsed A20.3 cells induced a T cell proliferative response that was 50-90% as good as the response generated when the antigen was present in the culture medium throughout the assay period. Pulsed control spleen cells were 40-70% as effective as spleen cells plus continuous antigen in this experiment. However, when <105 pulsed A20.3 cells were used in culture, no response was stimulated. In contrast, as few as 10 a tumor cells permitted a good response (40,123 cpm) in the presence of continuous antigen. Again, the proliferation obtained was magnified by the addition of the IL-1 preparation to the culture system.
A20.3 Presents Antigen to In Vivo Primed T Cells and to Long-Term Antigen-reactive T Cell Lines in a MHCorestricted
Fashion. In physiological situations, antigen-specific proliferative responses are only obtained when the antigen-reactive T cells and the APC are derived from donors that share common I region alleles (6, 7) . The antigen-specific T cell appears to recognize both an antigenic determinant and a syngeneic I regionencoded product on the surface of the APC. To determine whether A20.3 cells also presented antigen in such an MHC-restricted fashion, two different approaches were taken. First, Ir gene controlled systems were investigated. In such systems, it is known that for the APC to be able to present a given antigen, the donor of the APC must possess a responder allele in the I region (26) . A20.3 cells were tested for their ability to present antigen to T cells from (C57BL/6 × BALB/c)F1 mice primed with antigens to which one parent was a responder and the other parent a nonresponder. C57BL/6 mice possess an Ir gene enabling them to respond to collagen (27, 28) but are nonresponders to GI~; BALB/c mice have the reverse response pattern; they respond to GI~ but not to collagen. Both parental strains respond to PPD. In this experiment (Table VIII) 
A20.3 Presents Antigen in a Genetically Restricted Fashion to T Cells from a
Primed Donor 
K46R. 18, L10A6.2, and BALENLM 17.7.2 Present Antigen Poorly but Do Not Suppress
Responses Stimulated by A20.3. In Table III we showed that the M12.4 and X16C lines, like A20.3, stimulate an allogeneic MLR, These two tumors are also able to present PPD to primed T cells (Table V) . Three Ia antigen-positive B cell tumors--K46R. 18, L10A6.2, and BALENLM17.7.2--failed to stimulate an allogeneic MLR. The ability of these tumors to present PPD was tested in a series of experiments. The K46R. 18 tumor failed to present PPD to primed T cells in four of four experiments; the BALENLM 17.7.2 did produce T cell proliferation when used at the highest dose of 105 cells in one of three experiments, and the LIOA6.2 produced modest T cell proliferation to antigen when used at the highest dose of l0 s cells (Table X) . A possible explanation for the relatively poor ability of K46R.18, L10A6.2, and BAL-ENLM17.7.2 to present antigen was that these particular B cell tumors secreted suppressive material into the culture supernatant and thus masked or prevented a proliferative T cell response. This explanation does not appear to be correct because mixing cells from each of these three lines with A20.3 cells did not decrease the excellent proliferative response induced by the latter.
Discussion
The ability to present protein antigen or alloantigen to T cells in vitro has been shown to reside in an Ia antigen-positive, radioresistant, adherent, phagocytic, Ig-, FoR ÷ cell of the macrophage lineage (8) . More recently, Steinman and his co-workers (12) have provided convincing evidence that the lymphoid dendritic cell which is present in very small numbers in mouse spleen and that differs from the macrophage in being nonphagocytic and FcR-, is an extremely potent stimulator of alloreactive T cells, and Sunshine et al. (29) have further shown its effectiveness as an antigenpresenting cell. In addition, Chesnut and Grey (15) (Table V) .
The statement that tumor cells with the characteristics of B cells can serve as APC and stimulators of alloreactive responses depends upon the demonstration that contaminating macrophages remaining in the T cell population were not the source of the antigen-presenting function. Residual Ia antigen-positive APC could also potentially explain the alloantigenic stimulation we obtained because such macrophages in the responder cell population could take up, process, and re-present shed Ia antigens from the allogeneic tumor cells. That such a phenomenon does occur for cytotoxic cells has been shown by Weinberger et al. for purified H-2 complex proteins (24) .
To address this issue, three approaches were taken. First, we routinely treated the antigen-reactive and alloreactive nylon-passed T cell population with an ~xIa + C to deplete residual contaminating APC. The data obtained indicate that A20.3 ceils induced an excellent allogeneic and antigen-specific response in such pretreated T cell populations. The effectiveness of the aIa treatment was demonstrated by the lack of an antigen-specific response from the treated T cell population in the absence of added tumor or spleen cells as APC, even in the presence of a source of exogenous ILl. Second, we demonstrated that the inclusion of monoclonal antibodies directed against stimulator cell Ia molecules (MKD6 and 14.4.4S) could inhibit the proliferation observed; a monoelonal antibody directed against responder cell Ia molecules (10.2.16) was not inhibitory. Finally, the activation of allospecific and antigen-specific T cell lines by the A20.3 provides strong evidence that the tumor cell was itself providing the alloantigenic or protein antigen stimulus for T cell proliferation and not simply causing the differentiation or activation of residual Ia antigen-positive APC in the T cell population. Indeed, the capacity of A20.3 of H-2 a haplotype to activate primed F1 T cells accorded with the Ir phenotype of H-2 d cells. That is, A20.3 was capable of presenting GI_4b but not collagen to F1 T cells.
One interesting difference between the antigen-specific and allospecific responses studied in this paper was the necessity for the addition of an exogeneous source of ILl to obtain an allogeneic MLR. Although the addition of IL-1 clearly enhanced the proliferation generated by antigen-specific T cells, it was not necessary. A good proliferative response could be obtained in its absence. Studies by Weinberger et al. (24) suggested that a factor, presumably elaborated by the accessory cells, as well as macrophage-bound antigen, was necessary for stimulation of an alloreactive response. We have not been able to demonstrate constitutive IL-1 production by the B lymphoma cell lines, but it is possible that they do produce small amounts of IL-1 during the culture period. Alternatively, there may be another source of IL-1 in these cultures. These amounts might be sufficient to provide the second signal for antigenreactive T cells but insufficient to trigger alloantigen-reactive T cells.
We cannot explain the relatively poor ability of three of the six BALB/c B cell tumors to either stimulate an allogeneic MLR or to present antigen. It does not appear to be related to surface Ia antigen density (K. J. Kim, unpublished observation) nor do these tumors appear to produce suppressive secretory products. The diminished capacity of these cells to present antigen even in the presence of exogeneous IL-1 also makes a simple lack of secretion of this factor unlikely as an explanation. It is possible that there is yet another factor required to trigger antigen-reactive T cells and secreted by classic APC and by three of the six B cell tumors discussed here but not secreted by the three poorly stimulatory tumors. Alternatively, a defect in taking up and presenting antigen might be responsible, although the fact that these B cells tumors are nonstimulatory in an allogeneic MLR as well as poorly stimulatory in a protein antigen-specific response makes this less likely.
A cloned and easily obtainable population of B lymphoma cells endowed with the ability to present alloantigen and protein antigen to alloreactive and antigen-reactive T cells in an MHC-restricted fashion as efficiently on a per cell basis as the conventional APC should provide a useful model system to examine the biochemical events involved in antigen uptake, processing, and I region-associated antigen presentation to long-term continuous antigen-reactive T cell lines. Summary Several Ia-positive BALB/c B cell tumor lines were screened for their ability to present alloantigen and protein antigens to alloreactive and antigen-reactive T cells. Of six Ia-positive tumor lines studied, three were found to be effective as antigen presenting cells (APC). Indeed, on a per cell basis, one of the stimulatory lines, A20.3, was substantially more effective than whole spleen cells. The other three lines, although Ia-positive, were nonstimulatory. A20.3 was chosen for further study. This tumor appeared to behave like the conventional APC because (a) the tumor cells presented alloantigen, (b) they presented protein antigen in an MHC-restricted fashion to both primed donor T cells and to long-term continuous T cell lines, (c) alloantigen presentation was blocked by the inclusion of an anti-Ia antibody in the culture system, and (d) A20.3 cells could be effectively pulsed with antigen, although the continuous presence of antigen in the culture system resulted in a superior response. The addition of an exogenous source of interleukin 1 proved necessary to obtain an alloreactive but not an antigen-specific T cell response, although its inclusion did enhance the magnitude of antigen-stimulated proliferation. These tumor cells should prove useful in studying the biochemical events that occur during antigen processing and the requirements for T cell triggering by processed antigen in association with Ia molecules.
